Abstract
Second-generation antipsychotics have been growingly implicated in the acute and maintenance treatment for bipolar affective disorder (BAD). Risperidone long-acting injection (LAI) has been the first second-generation depot indicated for its maintenance treatment. However, its long-term motor side-effects, especially tardive dyskinesia (TD), has not been commonly reported or studied. The case reported here a bipolar patient with atypical presentation of TD involving only the crico-hyoid region of the neck associated with the use of risperidone LAI in adjunct to lithium and sodium valproate as maintenance therapy.
Keywords: Risperidone long-acting injection, bipolar, maintenance, tardive dyskinesia, crico-hyoid region
Current Drug Safety
Title:Atypical Presentation of Tardive Dyskinesia Associated with Risperidone Long-Acting Injection as Maintenance Treatment in Bipolar Affective Disorder: A Case Report
Volume: 7 Issue: 1
Author(s): Albert K.K. Chung
Affiliation:
Keywords: Risperidone long-acting injection, bipolar, maintenance, tardive dyskinesia, crico-hyoid region
Abstract: Second-generation antipsychotics have been growingly implicated in the acute and maintenance treatment for bipolar affective disorder (BAD). Risperidone long-acting injection (LAI) has been the first second-generation depot indicated for its maintenance treatment. However, its long-term motor side-effects, especially tardive dyskinesia (TD), has not been commonly reported or studied. The case reported here a bipolar patient with atypical presentation of TD involving only the crico-hyoid region of the neck associated with the use of risperidone LAI in adjunct to lithium and sodium valproate as maintenance therapy.
Export Options
About this article
Cite this article as:
K.K. Chung Albert, Atypical Presentation of Tardive Dyskinesia Associated with Risperidone Long-Acting Injection as Maintenance Treatment in Bipolar Affective Disorder: A Case Report, Current Drug Safety 2012; 7 (1) . https://dx.doi.org/10.2174/157488612800492807
DOI https://dx.doi.org/10.2174/157488612800492807 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Atypicality of Atypical Antipsychotics Revisited
Current Psychiatry Reviews The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets Susceptibility Genes for the Side Effect of Antipsychotics on Body Weight and Obesity
Current Drug Targets L-DOPA and Serotonergic Neurons: Functional Implication and Therapeutic Perspectives in Parkinson's Disease
Central Nervous System Agents in Medicinal Chemistry An Update on GABA Analogs for CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) Cognitive Impairment and Dementia in Patients with Parkinson Disease
Current Topics in Medicinal Chemistry Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity
Current Medicinal Chemistry Attention Deficit and Hyperactivity Disorder: Controversies of Diagnosis and Safety of Pharmacological and Nonpharmacological Treatment
Current Drug Safety L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment
Current Pharmaceutical Design Biomarkers in the Exhaled Breath Condensate of Healthy Adults: Mapping the Path Towards Reference Values
Current Medicinal Chemistry Is rTMS an Effective Therapeutic Strategy that Can Be Used to Treat Parkinson's Disease?
CNS & Neurological Disorders - Drug Targets Herbal Resources to Combat a Progressive & Degenerative Nervous System Disorder- Parkinson’s Disease
Current Drug Targets A Review on Emerging Drug Targets in Treatment of Schizophrenia
Current Drug Targets Molecular Biomarkers in Schizophrenia – Implications for Clinical Practice
Current Psychiatry Reviews Exploring Genetic Influences on Cognition: Emerging Strategies for Target Validation and Treatment Optimization
Current Drug Targets - CNS & Neurological Disorders Protein Homeostasis as a Therapeutic Target for Diseases of Protein Conformation
Current Topics in Medicinal Chemistry The Evolution of Pharmacological Treatment for Parkinsons Disease
Recent Patents on CNS Drug Discovery (Discontinued) EDITORIAL [Hot Topic Recognition of Functional Roles of Free Radicals Guest Editor: István Bokkon]
Current Neuropharmacology Therapeutic Potential of Natural Products in Parkinson’s Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery